2025
Optimal Magnitude of Blood Pressure Reduction and Hematoma Growth and Functional Outcomes in Intracerebral Hemorrhage
Li Q, Lv X, Morotti A, Qureshi A, Dowlatshahi D, Falcone G, Sheth K, Shoamanesh A, Murthy S, Viswanathan A, Goldstein J. Optimal Magnitude of Blood Pressure Reduction and Hematoma Growth and Functional Outcomes in Intracerebral Hemorrhage. Neurology 2025, 104: e213412. PMID: 39913881, PMCID: PMC11803522, DOI: 10.1212/wnl.0000000000213412.Peer-Reviewed Original ResearchConceptsSystolic blood pressure reductionSystolic blood pressureMagnitude of blood pressure reductionATACH-2 trialHematoma expansionMagnitude of SBP reductionAcute kidney injuryATACH-2Blood pressure reductionIntracerebral hemorrhageMm HgSBP reductionPost Hoc AnalysisFunctional outcomesHematoma growthAntihypertensive Treatment of Acute Cerebral Hemorrhage 2Poor outcomeHoc AnalysisMedian hematoma volumeModified Rankin Scale scoreSevere intracerebral hemorrhagePressure reductionMultivariable logistic regression assessed associationsRisk of poor outcomesAdmission systolic blood pressureOutcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial
Malas M, Hamouda M, Farber A, Menard M, Conte M, Rosenfield K, Strong M, Doros G, Powell R, Mena-Hurtado C, Gasper W, Schermerhorn M, Allievi S, Smolderen K, Dake M, Rymer J, Tuttle K. Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial. Journal Of Vascular Surgery 2025, 81: 945-956.e3. PMID: 39846933, DOI: 10.1016/j.jvs.2024.12.128.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmputation, SurgicalChronic Limb-Threatening IschemiaEndovascular ProceduresFemaleGlomerular Filtration RateHumansIschemiaKidneyLimb SalvageMaleMiddle AgedPeripheral Arterial DiseaseProspective StudiesRenal DialysisRenal Insufficiency, ChronicRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeVascular Surgical ProceduresConceptsChronic limb-threatening ischemiaChronic kidney diseaseDialysis-dependent patientsBEST-CLIChronic kidney disease stagePrimary trial outcomeRisk of amputationAssociated with lower mortalityEndovascular therapyAll-Cause MortalityHigh risk of poor outcomesRisk of poor outcomesEndovascular revascularizationKidney diseaseBEST-CLI trialOutcomes of lower extremity revascularizationAssociated with better survivalMultivariate Cox regression analysisBest Surgical TherapyIncreased reintervention rateStage 4 CKD patientsRisk of reinterventionGroup C patientsAdverse limb eventsChronic kidney disease severity
2024
Study protocol: Comparison of different risk prediction modelling approaches for COVID-19 related death using the OpenSAFELY platform
Collaborative T, Williamson E, Tazare J, Bhaskaran K, Walker A, McDonald H, Tomlinson L, Bacon S, Bates C, Curtis H, Forbes H, Minassian C, Morton C, Nightingale E, Mehrkar A, Evans D, Nicholson B, Leon D, Inglesby P, MacKenna B, Cockburn J, Davies N, Hulme W, Morley J, Douglas I, Rentsch C, Mathur R, Wong A, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Grieve R, Harrison D, Steyerberg E, Eggo R, Diaz-Ordaz K, Keogh R, Evans S, Smeeth L, Goldacre B. Study protocol: Comparison of different risk prediction modelling approaches for COVID-19 related death using the OpenSAFELY platform. Wellcome Open Research 2024, 5: 243. PMID: 39931522, PMCID: PMC11809169, DOI: 10.12688/wellcomeopenres.16353.2.Peer-Reviewed Original ResearchRisk prediction modelPrimary care electronic health records dataElectronic health record dataTime-varying measuresHealth record dataRisk of poor outcomesOpenSAFELY platformChronic disease settingsRestricted social contactDeath dataCOVID-19 related deathsWorld Health OrganizationCohort approachCOVID-19 deathsRecord dataCOVID-19Population of adult patientsHealth OrganizationRisk predictionOpenSAFELYSocial contactPerceived RiskPolicy changesRelated deathsAdult patientsSex Modifies the Severity and Outcome of Spontaneous Intracerebral Hemorrhage
Rivier C, Renedo D, Marini S, Magid‐Bernstein J, de Havenon A, Rosand J, Hanley D, Ziai W, Mayer S, Woo D, Sansing L, Sheth K, Anderson C, Falcone G. Sex Modifies the Severity and Outcome of Spontaneous Intracerebral Hemorrhage. Annals Of Neurology 2024, 97: 232-241. PMID: 39499118, DOI: 10.1002/ana.27123.Peer-Reviewed Original ResearchRisk of hematoma expansionHighest risk of hematoma expansionRisk of poor outcomesIntracerebral hemorrhageHematoma expansionHigh riskMale sexPoor outcomeOutcome of spontaneous intracerebral hemorrhageClinical characteristics of patientsStudies of intracerebral hemorrhageNon-traumatic intracerebral hemorrhageIndividual Patient Data Meta-AnalysisPatient data meta-analysisSpontaneous intracerebral hemorrhageSingle-center studyIntracerebral hemorrhage patientsHigh risk of expansionCharacteristics of patientsIntracerebral hemorrhage severityPoor functional outcomeRandomized clinical trialsData Meta-AnalysisHemorrhage volumeClinical characteristicsImpact of premorbid hypertension and renin-angiotensin-aldosterone system inhibitors on the severity of aneurysmal subarachnoid haemorrhage: a multicentre study
Zhong P, Lu Z, Li Z, Li T, Lan Q, Liu J, Chen S, Wang Z, Huang Q. Impact of premorbid hypertension and renin-angiotensin-aldosterone system inhibitors on the severity of aneurysmal subarachnoid haemorrhage: a multicentre study. Stroke And Vascular Neurology 2024, 10: e003052. PMID: 38889918, PMCID: PMC12107460, DOI: 10.1136/svn-2023-003052.Peer-Reviewed Original ResearchRenin-angiotensin-aldosterone systemWorld Federation of Neurological SurgeonsAneurysmal subarachnoid haemorrhageRenin-angiotensin-aldosterone system inhibitorsHunt-Hess scaleClinical grading scaleClinical outcomesUncontrolled hypertensionGrading scaleWorld Federation of Neurological Surgeons scaleRisk of adverse clinical outcomesHypertension statusElevated risk of poor outcomesSubarachnoid haemorrhageRisk of adverse outcomesComparison to patientsAdverse clinical outcomesRisk of poor outcomesNormal blood pressureMultivariate logistic regressionIntracranial aneurysm ruptureRisk of intracranial aneurysm rupturePremorbid hypertensionSystem inhibitorsMulticentre study
2023
COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore
Tan W, Tan J, Lim J, Tan R, Bin Lee A, Leong F, Lee S, Chai L, Tan T, Bin Abdul Malek M, Ong B, Lye D, Chiew C, Chng W, Lim S, Bharwani L, Tan I, Sundar R, Tan K. COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore. JAMA Oncology 2023, 9: 1221-1229. PMID: 37440245, PMCID: PMC10346511, DOI: 10.1001/jamaoncol.2023.2271.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosCancer survivorsVaccine doseSevere diseaseCohort studyTreated patientsProspective multicenter observational cohort studyCompeting-risk regression analysisMulticenter observational cohort studyMatched ControlsVaccine efficacyVaccine effectivenessRisk of poor outcomesWaning of vaccine effectivenessSevere COVID-19 disease outcomesMRNA vaccine doseRisk of deathObservational cohort studyMRNA-based vaccinesSocioeconomic statusSARS-CoV-2 DeltaRate ratiosCOVID-19 hospitalizationIncidence rateOmicron wave
2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals Of Oncology 2017, 28: 1098-1104. PMID: 28453693, DOI: 10.1093/annonc/mdx041.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenUnited States Preventive Services Task ForceRisk of prostate cancer-specific mortalityProstate cancer outcomesBlack raceMetastatic diseaseCancer outcomesProstate-specific antigen screeningRate of metastatic diseasePSA screening guidelinesCancer-specific mortalityRisk of poor outcomesStage of presentationPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menSEER databaseProstate cancerBlack menScreening guidelinesPoor outcomeRisk regressionRacial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Beard C, Martin N, Feng F, Kim S, Yu J, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Journal Of Clinical Oncology 2017, 35: 18-18. DOI: 10.1200/jco.2017.35.6_suppl.18.Peer-Reviewed Original ResearchProstate cancer-specific mortalityProstate-specific antigenRisk of prostate cancer-specific mortalityProstate-specific antigen screeningProstate cancer outcomesUnited States Preventive Services Task ForceBlack raceMetastatic diseaseCancer outcomesRate of metastatic diseaseCancer-specific mortalityStage of presentationRisk of poor outcomesPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menProstate-specificSEER databaseProstate cancerBlack menPoor outcomeRisk regressionBlack patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply